Objective To evaluate the clinical effectiveness of helicobacter pylori (HP) eradication in treating functional dyspepsia (FD) patients with HP infection. Methods The randomized controlled trials (RCTs) about HP eradication vs. general treatment for FD patients published by April, 2012 were searched in the following databases: CBM, CNKI, WanFang Data, PubMed, Ovid, EMbase and The Cochrane Library (Issue 1, 2012). According to the inclusion and exclusion criteria, two reviewers independently screened studies, extracted data, and evaluated the methodological quality. Then the meta-analysis was conducted using RevMan 5.1 software. Results The total 14 RCTs were included. Among all 2 665 patients involved in, 1 339 were in the treatment group, while the other 1 326 were in the control group. The results of meta-analysis showed that HP eradication was superior to general treatment for FD patients in clinical effects (RR=3.90, 95%CI 3.08 to 4.94, Plt;0.000 01), symptomatic score (WMD=?1.68, 95%CI ?1.88 to ?1.47, Plt;0.000 01), and improvement of upper abdominal pain (RR=2.84, 95%CI 2.02 to 3.99, Plt;0.000 01). Conclusion With obviously clinical effects, HP eradication can decrease the symptomatic score of dyspepsia, and especially improve upper abdominal pain. For the quality and quantity limitations of the included studies, more well-designed and double blind RCTs are required to further prove this conclusion.
ObjectiveTo investigate the protective effects and mechanism of selective histone deacetylases 6 (HDAC6) inhibitor 23BB in myoglobin-induced proximal tubular cell lines (HK-2).MethodsHK-2 cells were divided into 5 groups, including control group, myoglobin (200 μmol/L) group, myoglobin (200 μmol/L)+23BB (1.25 nmol/L) group, myoglobin (200 μmol/L)+4-phenylbutyric acid (2 mmol/L) group, and myoglobin (200 μmol/L)+23BB (1.25 nmol/L)+tunicamycin (25 ng/mL) group. Cells were collected at 24 hours after treatment. The endoplasmic reticulum (ER) stress-related gene mRNA level and marker protein expression were evaluated by RT-PCR and Western blotting, including glucose regulated protein 78 (GRP78), C/EBP homology protein (CHOP), inositol-requiring enzyme 1 (IRE1), PKR-like ER kinase (PERK), and activating transcription factor 6.ResultsIn in vitro study, ER stress-related mRNA of GRP78, IRE1α, PERK, and CHOP and marker protein expression of GRP78 and CHOP were found to increase in response to myoglobin treatment. Either administration of 23BB or 4-PBA could alleviate myoglobin-induced these changes.ConclusionThe protective effect of HDAC6 inhibitor 23BB is through the inhibition of myoglobin-induced ER stress in HK-2 cells.
Infectious cystitis is an inflammatory disease of the bladder wall caused by pathogenic microorganisms invading the urinary tract and is one of the most common types of urinary tract infections in clinical practice. At present, China lacks evidence-based clinical practice guidelines for the integrated diagnosis and treatment of infectious cystitis with Chinese and Western medicine. Consequently, significant variations exist in diagnostic and therapeutic strategies across medical institutions, and the recurrence rate remains relatively high. To further standardize clinical decision-making for patients with infectious cystitis and to promote the translation of the latest clinical research evidence into practice, the working group has initiated the development of the Guidelines on Integrated Chinese and Western Medicine in the Diagnosis and Treatment of Infectious Cystitis. The guideline development will be conducted in accordance with the World Health Organization (WHO) handbook for guideline development, following the standards and requirements of the GRADE system and the Reporting Items for Practice Guidelines in Healthcare (RIGHT). It will also incorporate national health policies, classical medical texts, existing guidelines or consensuses, and the distinctive characteristics of traditional Chinese medicine (TCM) diagnosis and treatment. This proposal systematically outlines the background and significance of the guideline, the composition of the working group, the construction of clinical questions and the identification of outcome indicators, the methodology of evidence collection and systematic evaluation, the formation of recommendations and the consensus process, etc., to provide a methodological basis and technical guidance for the scientific development and standardized release of subsequent guidelines.